Harrow (Nasdaq: HROW), a prominent North American eyecare pharmaceutical company, has announced that its management team will attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting in Stockholm, Sweden, scheduled from July 17-20, 2024. This premier event gathers leading retina specialists, researchers, and industry leaders worldwide to discuss the latest advancements and research in retinal health and treatment.
“We are looking forward to participating in the ASRS Annual Meeting and connecting face-to-face with our expanding customer base of U.S. retina specialists,” said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. “We intend to discuss Harrow’s growing portfolio of ophthalmic pharmaceutical products, including IHEEZO®, a novel topical anesthetic gel used for ocular surface anesthesia during procedures like intravitreal injections by retina specialists. Additionally, we are excited to update attendees on our progress toward reintroducing TRIESENCE®, the only product indicated for vitreous visualization during vitrectomy and the treatment of posterior uveitis and other conditions affecting the posterior segment. Our participation underscores Harrow’s dedication to serving the U.S. retina community.”
For more details about Harrow’s ophthalmic pharmaceutical product portfolio, including Full Prescribing Information, please visit their website.
To arrange a meeting with Harrow’s management team during the conference, please contact Jamie Webb, Director of Communications and Investor Relations, at [email protected].
The ASRS Annual Meeting is a pivotal gathering for the retina specialist community, featuring scientific sessions, workshops, and networking opportunities. Harrow aims to foster collaboration, drive innovation, and raise awareness within the retina community about its extensive range of ophthalmic pharmaceutical products through its participation in this event.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company focused on discovering, developing, and commercializing innovative ophthalmic pharmaceutical products for the North American market. Harrow is committed to assisting eyecare professionals in preserving sight by providing accessible and affordable prescription and non-prescription pharmaceutical products to millions of patients annually.
